Sacituzumab govitecan shows efficacy in metastatic urothelial cancer after progression on CPIFebruary 17th 2023
“These data support further evaluation of sacituzumab govitecan—alone or in combination—in patients with metastatic urothelial carcinoma who progressed after prior CPI therapy,” says Daniel P. Petrylak, MD.
Clinical complete response may guide eligibility for cystectomy in MIBCFebruary 17th 2023
In the the phase 2 HCRN GU 16-257 trial, 33 patients with muscle-invasive bladder cancer were eligible to forego cystectomy and continue 240-mg maintenance nivolumab monotherapy every 2 weeks for 8 cycles followed by surveillance.
Blood-based assay shows promise in detecting liquid and solid tumors, including prostate cancerSeptember 15th 2022
"When the blood tests were positive, workups were typically completed in less than 3 months. I think this is really a new concept. It shows it is feasible to detect cancers using blood tests," said Deb Schrag, MD, MPH.
Lenvatinib/pembrolizumab efficacy in renal cell carcinoma sustained with longer follow-upSeptember 11th 2022
“These data clearly show that the efficacy benefit observed at the primary analysis was robust and maintained with longer follow-up, once again supporting lenvatinib and pembrolizumab as a standard of care in first-line advanced RCC,” said Camillo G. Porta, MD.